Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Urinary Bladder Neoplasms 2Hyperthermia 2Ureteral Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Retinoblastoma 1Oropharyngeal Neoplasms 1Laryngeal Neoplasms 1Hypopharyngeal Neoplasms 1Head and Neck Neoplasms 1Carcinoma, Hepatocellular 1

Interventions

pembrolizumab 4enfortumab vedotin 4Specimen Handling 3Magnetic Resonance Spectroscopy 3tamibarotene 1Standard of Care 1Radiotherapy 1Practice Guidelines as Topic 1Plasmapheresis 1Plasma Exchange 1Nephroureterectomy 1Morphine 1Hyperthermia, Induced 1Cystectomy 1Cisplatin 1Central Venous Catheters 1Bupivacaine 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Ureteral Neoplasms × Hyperthermia, Induced × Clear all
NCT06764095 2026-02-12

Enfortumab Vedotin and Pembrolizumab With Cystectomy and/or Ureterectomy for Locally Advanced or Metastatic Bladder and Upper Urothelial Tract Cancer, CAST-AI Trial

Mayo Clinic

Phase 4 Recruiting
75 enrolled
Genitourinary

Urinary Bladder Neoplasms, Ureteral Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡